cached image
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Matthew M. Ford is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2004 |
Ford, Matthew M |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Neurosteroid Modulation of Ethanol Intake and Reward @ Oregon Health and Science University
DESCRIPTION (provided by applicant): The goal of the proposed research is to delineate a mechanistic role for the neurosteroid allopregnanolone (ALLOP) at the level of the ventral tegmental area (VTA) on ethanol self-administration patterns and brain reward pathway activation. Gamma-aminobutyric acid type A (GABA-A) receptors in the VTA are thought to mediate, in part, ethanol's subjective and motivational effects; presumably via modulation of the mesolimbic dopaminergic projection from the VTA to the nucleus accumbens (NAc). The neurosteroid ALLOP, an endogenous positive modulator of GABA-A receptors, has been demonstrated to potentiate maintained and reinstated operant responding for ethanol as well as augment ethanol self-administration. The first specific aim will determine the effects of manipulating the levels and metabolism (sulfonation) of ALLOP within the VTA on established ethanol consumption patterns in mice. Studies in the second research aim will assess the impact of VTA-applied ALLOP on NAc DA and will evaluate ALLOP's interaction with ethanol-stimulated changes in extracellular NAc DA levels. Results from these experiments will provide valuable insights into the mechanisms underlying neurosteroid modulation of ethanol intake and reward.
|
1 |
2007 — 2011 |
Ford, Matthew M |
K01Activity Code Description: For support of a scientist, committed to research, in need of both advanced research training and additional experience. |
Nicotine Modulation of Ethanol Consumption and Discrimination @ Oregon Health and Science University
[unreadable] DESCRIPTION (provided by applicant): The overall goal of this Mentored Research Scientist Award (K01) application is to explore the behavioral and pharmacological ramifications of concurrent ethanol and nicotine administration while providing the candidate (Dr. Matthew Ford) with an enriched training environment and a diversified research experience that will serve to nurture his transition to an independent investigator. The candidate will complement already familiar and established self-administration procedures by working closely with the mentor/sponsor (Dr. Kathleen Grant) to establish proficiency in training drug discriminations for single drugs and drug mixtures. In addition to learning the theory behind the drug discrimination procedure, the concepts of associative blocking and overshadowing will be directly studied in relation to ethanol and nicotine interactions in the generation of a conditioned drug cue. The candidate will also become familiar with several pharmacological strategies that are commonly employed to evaluate the salience and characteristics of a discriminative drug cue, such as, generalization testing and dose-response curve assessments. The sponsor will also guide the candidate in the practice of data analysis, data interpretation and the identification of procedural limitations as specifically related to the drug discrimination procedure. The proposed studies will test specific aims that address the influence of nicotine exposure history and dose on ethanol selfadministration outcomes and evaluate the impact of nicotine on the stimulus control exhibited by an interceptive ethanol cue. This mentored training opportunity will permit the candidate to accumulate additional research skills and experience in neuropharmacological and behavioral approaches to studying alcohol and other abused drugs, and will cement a solid foundation on which to stand as an independent principal investigator. Relevance: An estimated 90% of alcoholics engage in smoking behavior. Through the investigation of concurrent nicotine and ethanol administration, this research application seeks to arrive at a more complete understanding of the functional interactions between nicotine and ethanol. This investigational approach will provide valuable insights into the prevalence of their co-abuse liability, with the added potential to identify treatment strategies for ethanol and nicotine co-dependence. [unreadable] [unreadable] [unreadable]
|
1 |
2016 — 2018 |
Ford, Matthew M |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Gdnf Gene Therapy to Block Relapse of Heavy Alcohol Use in Monkeys @ Oregon Health & Science University
? DESCRIPTION (provided by applicant): Alcoholism and alcohol use disorders represent a major public health problem, and are associated with devastating social and economic burdens. Despite active research and development of pharmacotherapies for the treatment of alcoholism, FDA-approved medications are often insufficient in sustaining long-term abstinence in treatment-seeking individuals. This stark reality is made clear by the fact that upwards of 90% of alcoholics relapse at least once over a four year period following treatment onset. The purpose of this project is to establish a new paradigm for the treatment of alcoholism and alcohol use disorders; one that site- specifically targets a neuro-regenerative process, reverses dependence-associated deficits in reward pathway function, circumvents the reliance on protracted patient compliance, and exhibits a permanent effect once introduced. We believe that gene therapy that culminates in the overexpression of glial-derived neurotrophic factor (GDNF) within the ventral tegmental area (VTA), a key component of the reward neurocircuitry, is such a treatment paradigm. Preliminary work conducted in rodents indicated that elevated expression of intra-VTA GDNF blocks the escalation of alcohol drinking in naive animals and significantly attenuates excessive drinking in alcohol-experienced animals whereas suppression of endogenous GDNF in the VTA enhances the progression to heavy alcohol use. A crucial next step in advancing the translation application of this treatment paradigm to human alcoholics is to first demonstrate that a similar intervention in non-human primates (NHPs) will yield a comparable benefit in reducing relapse risk. Aim 1 of this project will establish heavy alcohol self- administration in a cohort of male cynomolgus monkeys during a 6-month open access period. These methods have been validated and replicated for over a decade, with monkeys developing binge-like drinking patterns of alcohol use that resemble those observed in human alcoholics. Aim 2 will evaluate the efficacy of GDNF gene therapy in preventing relapse and the continuation of heavy drinking. An adeno-associated virus serotype 2 (AAV2)-GDNF or control vector will be bilaterally infused into the VTA of each monkey following a 1-month period of abstinence, and alcohol will be re-introduced under open access conditions and self- administration patterns will be monitored during multiple withdrawal-relapse cycles. We hypothesize that AAV2-GDNF treatment will prevent relapse-like drinking patterns and reduce the number of heavy drinking days by attenuating the incidence of binges (large bout sizes) that produce intoxicating blood alcohol concentrations. In summary, we believe this will be a transformative approach for the treatment of alcoholism that may also be applicable for the treatment of other life-threatening addictions. If successful, then our in-life data will be includd in a briefing package to the U.S. Food & Drug Administration in order to advance this candidate therapeutic through an Investigation New Drug (IND) submission for future clinical testing.
|
1 |